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ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO SCT) IN ADULT
ALL: DOES PROPHYLACTIC DONOR LYMPHOCYTE INFUSION (DLI)
IMPROVE SURVIVAL?
Arnold, R., Lutz, C., Neuburger, S., Tamm, I., Rosen, O., Do¨rken, B.,
Massenkeil, G. Department of Hematology/Oncology, University Hospi-
tal Charite´, Campus Virchow Klinikum, Berlin, Germany.
Patients with high-risk (HR) ALL (Ph, B-lineage high WBC
and/or CR 4 weeks, mature T-ALL) are candidates for allo SCT in
CR-1. Despite SCT in CR-1, relapse rates are high and increase in
advanced stages. Prognosis of relapsed ALL after SCT is poor and
could not be improved by therapeutic DLI. We therefore studied the
effect of prophylactic DLI on the incidence of relapse after allo SCT.
Between 1995 and 2004, 105 adult HR-ALL patients (median, 28
years [17–54]) (CR-1, n  45; CR-1, n  60) underwent allo SCT
(related, n  51; unrelated, n  54) after standard (n  100) or
reduced-intensity conditioning (n 5). Median follow-up of all ALL
patients was 10 months (range, 0.7–112 months). Since 1998, prophy-
lactic DLI was given to 24 of 105 patients without active GvHD. One
DLI was given on d111 (29–324). In median, the patients received
2 DLIs (1–4) with a total of 2.37 (0.1–20.6)  107 CD3 cells/kg;
18/24 patients (75%) are alive in CR and 6/24 (25%) are dead. A total
of 81 of 105 patients received no prophylactic DLI; 27 of these 81 are
alive in CR (33%) and 54 are dead (67%). The probability of survival
at 3 years was 0.41 for all 105 patients. Overall survival is 0.77 for the
patients with DLI and 0.29 for those without DLI (P.001). Stage of
disease at SCT (CR-1 vs CR-1) was a signiﬁcant factor for survival
at 3 years: 0.55 versus 0.31 (P  .008). Prophylactic DLI versus no
DLI improved survival after allo SCT either in CR-1 (0.60 vs 0.38;
P  .089) or  CR-1 (0.49 vs 0.20; P  .004). Better survival for the
DLI group was caused by decreased relapse probability in patients
with DLI compared to those without DLI: 0.56 versus 0.74 (P 
.002). Our data support a GvL effect induced by DLI in HR-ALL
patients, leading to a decreased relapse rate and improved survival
after allo SCT.
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ADULT TRANSPLANT OUTCOMES, SINGLE VERSUS POOLED CORD
BLOOD TRANSPLANTS
Wofford, J.D.1; Regan, D.M.1; Creer, M.H.2 1. St. Louis Cord Blood
Bank at SSM Cardinal Glennon Children’s Hospital, St. Louis, MO; 2.
St. Louis University Health Sciences Center, St. Louis, MO.
Adequate cell dose can be a limiting factor in using umbilical cord
blood (UCB) for adult transplantation; therefore, clinical protocols to
combine 2 UCB products have been developed. Adult data using
UCB products from the SLCBB was evaluated to determine if aug-
mentation of cell dose increases the safety of adult transplant. We
evaluated 106 cord blood unit transplants performed at 27 transplant
centers for adult patients (18 years of age) in which minimum 0–3
month outcomes and postthaw total nucleated cell count (TNC) were
reported, for pooled UCB transplants where both units infused were
from the SLCBB. Population characteristics include an even distri-
bution in gender, primarily treated for malignant diseases (95.1%),
median age of 43.8 years (range, 18.6–64.8), median weight of 72.0 kg
(range, 41.0–120.4). For single-cord blood transplants, units provid-
ing amedian postprocessing dose of 2.6107 cells/kg (range, 1.1–8.5)
were selected, but postthaw data indicates that only a median cell dose
of 2.0 107 cells/kg (range, 0.62–6.9) were infused. In the dual-cord
protocol, 2 units chosen to supply a median postprocessing dose of
4.7  107 cells/kg (range, 2.8–6.7) yielded a median infused dose of
3.6 107 cells/kg (range, 2.3–5.7) once thawed. TNC recoveries after
cryopreservation average 80%, but the impact is more profound in the
single transplant setting, where cell dose is diminished to 2.0 107
cells/kg in 51.8% of all cases, a dose proven to be associated with less
successful outcomes. When combining 2 units, a cell dose of 2.0
107 cells/kg was maintained in all cases. This ﬁnding led the bank to
evaluate potential differences in overall survival and neutrophil en-
graftment between the 2 transplant populations. Probabilities were
estimated by the Kaplan-Meier method. Median time to ANC 
500/mm3 was similar in both groups (pooled 18 days, n  21; single
21 days, n  73; P  .3027), but the difference in overall survival
between the 2 groups approached signiﬁcance (P  .0555). Overall
patient survival was 13.26 months in the pooled setting (n  23) and
3.32 months in the single-cord setting (n  83). Because TNC
recovery is unaffected by product size, selection of a single UCB unit
for transplant in adults based on the postprocessing cell dose may
result in a less than adequate dose. Preliminary data indicate that
pooling 2 units uniformly allows the maintenance of a cell dose of 
2  107 cells/kg, resulting in improved patient outcome.
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RESULTS OF THE CORD BLOOD TRANSPLANTATION STUDY (COBLT):
CLINICAL OUTCOMES OF 193 UNRELATED DONOR UMBILICAL CORD
BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS WITH MALIG-
NANT CONDITIONS
Kurtzberg, J.1; Carter, S.L.2; Baxter-Lowe, L.A.3; Feig, S.A.4; Gui-
nan, E.C.5; Kamani, N.R.6; Kapoor, N.7; Delaney, C.8; Haut, P.R.9;
Wall, D.10; Kernan, N.A.11 1. Duke University Medical Center,
Durham, NC; 2. The EMMES Corporation, Rockville, MD; 3. Uni-
versity of California, San Francisco, CA; 4. University of California, Los
Angeles, CA; 5. Dana Farber Cancer Institute, Boston, MA; 6. Chil-
dren’s National Medical Center, Washington, DC; 7. Children’s Hos-
pital of Los Angeles, Los Angeles, CA; 8. Fred Hutchinson Cancer
Research Center, Seattle, WA; 9. James Whitcomb Riley Hospital for
Children, Indianapolis, IN; 10. Texas Transplant Institute, San Anto-
nio, TX; 11. 1Memorial Sloan-Kettering Cancer Center, New York, NY.
The Cord Blood Transplantation Study (COBLT), supported by
the National Heart, Lung, and Blood Institute, created 2 unrelated
donor cord blood banks with an inventory of approximately 8,000
units (CBUs). Six core and 22 collaborating transplant centers en-
rolled patients on a phase II clinical trial employing a common
preparative regimen (TBI/cyclophosphamide/ATG) and prophylaxis
against GvHD (cyclosporine/steroids). Children (n  193; 61%
males, 57% Caucasian, 52% CMV) with ALL, ANLL, MDS or
CML not in relapse or blast crisis, median age 7.8 years were trans-
planted with  5/6, 4/6, or 3/6 HLA-matched CBUs as deﬁned by
intermediate-resolution HLA typing at Class IA and IB and high-
resolution typing at DRB1. The primary study end point was 180-day
survival. CBUs delivering a median precryopreservation cell dose of
5.5  107 total nucleated cells (TNC)/kg and 1.5  105 CD34
cells/kg were selected from COBLT or other banks. The cumulative
incidence of neutrophil and platelet engraftment with  90% donor
cells was 73% at a median of 28 days and 52% by 180 days, respec-
tively. The cumulative incidence of grade III and IV acute GvHDwas
20%, and that of chronic GvHD was 22%. HLA mismatching at the
5/6, 4/6, or 3/6 level by original lower resolution or retrospective
high-resolution DNA typing performed on donor/recipient pairs did
not correlate with engraftment, GvHD, or survival. In multivariate
analysis, seronegativity for CMV was the only factor that correlated
with improved survival. TNC and CD34 dose correlated with en-
graftment of neutrophils and platelets. The COBLT study represents
the ﬁrst multi-institutional, prospective clinical trial in children with
malignancies undergoing UCBT. Survival in patients transplanted
with low-resolution 4/6 and 5/6 matched grafts is favorable. Partially
HLA-matched unrelated cord blood donors provide access to trans-
plantation therapy for pediatric patients with malignancies lacking a
matched living donor.
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